Dose Response to Topical Glyceryl Trinitrate in Patients With Raynaud's Phenomenon

Raynaud's Phenomenon Clinical Trial

Official title:

A Phase I Trial of the Pharmacodynamic Dose Response to Topical Trinitrate in Patients With Raynaud's Phenomenon

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00700518
• Other study ID #: P150-005
• Status: Completed
• Phase: Phase 1
• First received: June 13, 2008
• Last updated: December 29, 2008
• Start date: June 2008
• Est. completion date: November 2008

Study information

• Verified date: December 2008
• Source: Procris Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the blood flow response to topical Glyceryl Trinitrate when applied to the skin of patient's fingers with Raynaud's Phenomenon.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: November 2008
• Est. primary completion date: November 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Male and female volunteers aged between 18 and 50 inclusive

• Subject has idiopathic RP (patient may have undifferentiated connective tissue disease with positive ANA) diagnosed for more than two (2) years

• If a female, subject must be non-pregnant and non-lactating

• The subject has provided written informed consent prior to admission to this study

Exclusion Criteria:

• History of clinically relevant medical illnesses (not considering RP) that in the Investigator's opinion may jeopardize subject's safety or interfere with participation in the study, including but not limited to hemoglobinopathy, hemophilia, clinically significant retinal abnormalities, unstable hypertension, liver diseases, chronic pulmonary diseases, significant cardiovascular diseases, diabetes, thyroid diseases, gout, psychiatric or psychological disorders, CNS trauma or active seizure disorders, allergic or immunologically mediated disorders

• History in the past five (5) years of drug or alcohol abuse

• History in the past five (5) years of vascular migraine or other chronic severe headache

• History in the past five (5) years of autonomic neuropathy or postural hypotension

• Unwilling or unable to comply with the restrictions outlined in the protocol

• Current use of smoking cessation treatment, including nicotine patches

• History of drug allergies, anaphylaxis or laryngeal oedema, including allergy to GTN, propylene/ethylene glycol or common moisturizing creams

• Use of any nitrate medication or any phosphodiesterase inhibitor within three (3) days prior to or intended use one (1) day following each dosing with study drug

• Currently treated for hypertension

• Currently receiving treatment for prevention and/or treatment of RP

• Use of any investigational medication within 30 days prior to dosing with study medication or scheduled to receive an investigational drug other than during the course of this study

• Open skin lesions or pathological condition (including, but not limited to, infection) in the area where the study medication is to be applied

• Use of topical corticosteroid to the hand or fingers within 10 days of treatment with study drug

• Withdrawal of consent at any time during the study

• Any condition, which compromises ability to give informed consent or to communicate with the investigator as required for the completion of this study

• Previously enrolled in the study

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Raynaud Disease
• Raynaud's Phenomenon

Intervention

Drug:
• placebo cream
placebo cream applied to 2 adjacent fingers of non-dominant hand one time
• Glyceryl Trinitrate
0.6mg of Glyceryl Trinitrate applied to 2 adjacent fingers on non-dominant hand one time
• Glyceryl Trinitrate
1.2mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
• Glyceryl Trinitrate
1.8mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
• Glyceryl Trinitrate
2.4 mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time

Locations

Country	Name	City	State
United States	University of Iowa-Institute for Clinical and Translational Science	Iowa City	Iowa

Sponsors (1)

Lead Sponsor	Collaborator
Procris Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Investigate vascular responses to topical Glyceryl Trinitrate versus placebo in patients with Raynaud's using laser Doppler imaging to measure blood flow		6 visits no less than 10 hours between visits	Yes
Secondary	Evaluate the dose proportionality of the microvascular response to topical Glyceryl Trinitrate		6 visits no less than 10 hours between visits	Yes
Secondary	Compare the systemic versus topical effect of Glyceryl Trinitrate on vascular response.		6 visits no less than 10 hours between visits	Yes